Completed PHASE2 NCT00000587

Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection

Sponsor: Thomas Jefferson University

Conditions Acquired Immunodeficiency Syndrome Anemia Blood Disease HIV Infections Hematologic Diseases

Interventions erythropoietin, recombinant

Updated 6 times since 2017 Last updated: Nov 16, 2021 Started: Sep 30, 1988 Primary completion: Jan 31, 2005 Completion: Jan 31, 2005

Listed as NCT00000587, this PHASE2 trial focuses on Acquired Immunodeficiency Syndrome and Anemia and remains completed. Sponsored by Thomas Jefferson University, it has been updated 6 times since 1988, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 1988

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Thomas Jefferson University

Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.